Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | NR1H4 | Q96RI1 | 5/20 | 0.44 |
| ▸ | PTGDR2 | Q9Y5Y4 | 10/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.40 |
| ▸ | TP53 | P04637 | 1/20 | 0.40 |
| ▸ | GLA | P06280 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.39 |
| ▸ | CYP26B1 | Q9NR63 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL479952 | 1.00 | KDM4E (0.50) | KDM4ENR1H4PTGDR2MAPTMAPK1 | |
| SCHEMBL479919 | 0.95 | PTGDR2 (0.46) | KDM4ENR1H4PTGDR2CYP26A1CYP26B1 | |
| SCHEMBL752162 | 0.92 | SMN1; SMN2 (0.46) | KDM4EMAPTMAPK1NPSR1 | |
| SCHEMBL479651 | 0.92 | SMN1; SMN2 (0.46) | KDM4EMAPTMAPK1NPSR1 | |
| SCHEMBL753147 | 0.91 | MAPT (0.43) | MAPTMAPK1NPSR1MEN1TP53 | |
| SCHEMBL479734 | 0.91 | MAPT (0.43) | MAPTMAPK1NPSR1MEN1TP53 | |
| SCHEMBL479894 | 0.90 | NR1H4 (0.44) | KDM4ENR1H4PTGDR2MEN1KMT2A | |
| SCHEMBL752950 | 0.90 | NR1H4 (0.44) | KDM4ENR1H4PTGDR2MEN1KMT2A | |
| SCHEMBL479788 | 0.89 | NR1H4 (0.41) | KDM4ENR1H4PTGDR2MEN1FFAR1 | |
| SCHEMBL480861 | 0.87 | MAPT (0.44) | MAPTMAPK1NPSR1MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411361-B1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN LA ROCHE (CH) | 2014-06-18 | — | — | EP | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-8138189-B2 | Substituted benzene compounds as modulators of the glucocorticoid receptor | HOFFMAN-LA ROCHE INC. (US) | 2012-03-20 | — | — | US | disclosed |
| WO-2010108902-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-09-30 | — | — | WO | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | HOFFMANN-LA ROCHE, INC. | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249139-A1 | 1,1,1-TRIFLUORO-2-HYDROXYPROPYL COMPOUNDS | NR3C1, NR3C2, CRHR1 | KDM4E 1499/4885NR1H4 195/4885PTGDR2 465/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.